Non-Alcoholic Steatohepatitis Treatment Market Growth and Trends: Key Insights into Market Opportunities for 2025-2034
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theNon-Alcoholic Steatohepatitis Treatment Market?
The surge in insulin resistance, which is the condition when the body’s muscles, fat, and liver cells fail to adequately react to insulin, thereby leading to higher blood sugar levels, is a key driver in the rise of the non-alcoholic steatohepatitis treatment market. This condition is often related to unhealthy lifestyles, overconsumption of sugar, and genetic predispositions. The need for treating insulin resistance has amplified due to the surge in cases of diabetes and other liver-related disorders with non-alcoholic steatohepatitis treatments. As per data from the International Diabetes Federation based in Belgium, 537 million people aged 20 to 79, or one out of every ten, had diabetes in January 2022 and this number is projected to climb to 643 million by 2030 and 783 million by 2045. Similarly, new cases of liver cancer are forecasted to hit 41,630 in 2024, an increase from 41,210 in 2023, according to the US-based American Cancer Society in January 2024. Hence, the rising occurrence of insulin resistance caused by various liver ailments and diabetes is expected to bolster the non-alcoholic steatohepatitis treatment market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
How Will the Growth Rate of theNon-Alcoholic Steatohepatitis Treatment Market Impact Industry Trends by 2034?
The market size for non-alcoholic steatohepatitis treatment has seen steep growth in recent years. It is projected to expand from $2.6 billion in 2024 to $3.6 billion in 2025, with a compound annual growth rate (CAGR) of 38.5%. Elements contributing to the growth during the historical period include an increase in NASH cases, enhanced awareness and diagnosis, changes in lifestyle and an obesity crisis, advancements in clinical research, improvement in healthcare infrastructure and accessibility, supportive regulatory frameworks, and ongoing clinical trials.
Anticipated to experience significant expansion in the coming years, the market size for non-alcoholic steatohepatitis treatment is projected to surge to $13.83 billion by 2029, with a compound annual growth rate (CAGR) of 40.0%. The predicted growth during the forecast period is due to factors such as the progression in drug development, heightened disease consciousness, an increasing prevalence and risk factor, and a shift towards bespoke medicine. The forecast period is expected to showcase trends like a patient-focused approach, technological progress, targeted therapies, regulation changes, and research advancements.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595
Which Upcoming Market Trends and Innovations Are Set to Influence theNon-Alcoholic Steatohepatitis Treatment Market’s Path Forward?
The trend of developing drugs for non-alcoholic steatohepatitis (NASH) is gaining prominence in the NASH treatment market. Numerous firms are putting their resources towards the development of innovative medicines for liver ailments, with a reduced drug side effect profile. For example, in May 2022, Pfizer Inc., a prominent pharmaceutical and biotechnology corporation from the United States, was awarded a grant by the U.S. Food and Drug Administration (FDA) for a fast-track designation to expedite the development of their NASH drug, namely ervogastat and clesacostat. The Fast Track is a process specifically designed to speed up the development of Pfizer’s investigational combination therapy for treating NASH with liver fibrosis named as, ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Who Are the Dominant Market Players Pushing the Boundaries of theNon-Alcoholic Steatohepatitis Treatment Market?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
Order Your Report Now For A Swift Delivery:
What Are the Core Segments of the Non-Alcoholic Steatohepatitis Treatment Market, and How Do They Contribute to Growth?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=8595&type=smpGlobal Non-Alcoholic Steatohepatitis Treatment Market, Global Non-Alcoholic Steatohepatitis Treatment Market Report, Global Non-Alcoholic Steatohepatitis Treatment Market Trends, Global Non-Alcoholic Steatohepatitis Treatment Market Size
Browse Through More Reports Similar to the Gobal Non-Alcoholic Steatohepatitis Treatment Maret 2025, By The Business Research Company:
Protein Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report
Nutritional Analysis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report
Probiotics Dietary Supplements Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
